Presentation of Q3 results including outlook

Oncoinvent would like to extend an invitation to a short update on the company and a presentation on Q3 report including outlook. The presentation will be held on Thursday 23. November 2023 at 10:00 AM in the offices of Carnegie, Fjordalléen 16, Oslo, 5. floor, Meeting room: Verftet. It will also be possible to attend virtually.

To attend, please register with ir@oncoinvent.com. Logon details will be distributed to registered attendees.


Oncoinvent ønsker med dette å invitere til en kort status oppdatering og presentasjon av 3. kvartal inkludert veien videre. Presentasjonen vil holdes torsdag 23. november 2023, kl. 10:00 i lokalene til Carnegie, Fjordalléen 16, Oslo, 5. Etasje, Møterom: Verftet Det vil også være mulig å delta virtuelt.

Vi ber om at deltakere registrerer seg ved å sende en e-post til ir@oncoinvent.com. Eventuelle påloggingsdetaljer vil distribueres deretter.

Organiser: Oncoinvent / Carnegie and DnB
Venue:

Carnegie, Fjordalléen 16, Oslo, 5. floor,
Meeting room: Verftet.


Date: 23 November 2023
Program:

Øystein Soug

Chief Executive Officer

soug@oncoinvent.com

Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.  

Mr. Soug holds an MSc in Economics and Financial Markets from Universität St. Gallen in Switzerland in 1997

Anders Månsson

Chief Executive Officer

mansson@oncoinvent.com

Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.

Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.